Project Grant K23HL173628
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $191K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $188,892 Project Grant to the University of Washington to support research on the role of CD163+ blood monocytes and lung macrophages in progressive pulmonary fibrosis. This 5-year grant, starting August 1, 2025, will fund a physician-scientist's research plan that leverages the university's expertise in immunology, bioinformatics, and lung biology to...
- This $638,900 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of California, San Francisco (UCSF) to elucidate the role of distinct fibroblast subsets in the pathogenesis of silicosis, a severe and often fatal lung disease caused by exposure to crystalline silica. The research aims to characterize the lineage trajectories and functional contributions of these unique fibroblast populations...
- This federal Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $107,752 to Duke University to investigate the mechanisms of lung fibrosis. The research aims to evaluate epithelial cell-fibroblast interactions contributing to fibroblast activation through the CTHRC1-TGFβ signaling pathway, in the context of bronchiolitis obliterans and idiopathic pulmonary fibrosis. The 2-year project leverages Duke's...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...
- The National Heart Lung and Blood Institute (NHLBI), through its Cardiovascular Diseases Research program (CFDA 93.837), awarded a $172,724 project grant to The Regents of the University of California, San Francisco (UCSF) on February 28, 2025. The grant supports research to investigate the epigenetic signatures and gene regulatory networks driving the trans-differentiation of alveolar type II (AT2) cells into airway-like basal cells under homeostatic conditions and in the context of fibrotic...
- This federal Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the role of purinergic signaling in fibroblast activation and lung fibrosis. The $728,577 grant, awarded to the Regents of the University of California, San Francisco, aims to investigate the mechanisms by which the ATP receptor P2RX4 influences fibrotic pathways in lung fibroblasts. The research seeks to elucidate the...
- This $386,756 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a research project to develop an exosomic signature for rapidly progressive idiopathic pulmonary fibrosis (IPF). The principal investigator, Dr. Christina Eckhardt, will leverage existing IPF patient cohorts and data to identify extracellular vesicle-associated microRNAs that can quantify and predict the risk of accelerated IPF...
- This federal Project Grant award of $722,584 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research on the role of the desmosome-keratin intermediate filament network in lung epithelial injury, repair, and regeneration. The research aims to explore how dysfunction or loss of this network may contribute to idiopathic pulmonary fibrosis (IPF). The award was made to Tulane University, a private research institution with expertise in...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $542,402 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to a research partnership between Henry Ford Health and Michigan State University Health Sciences. The grant aims to identify drug compounds that can reverse profibrotic gene expression patterns in idiopathic pulmonary fibrosis (IPF), a debilitating lung disease with limited treatment options. Through a sub-award, Corewell Health will provide IPF...
- The Project Grant award titled "Alveolar Epithelial Stress Signaling in Lung Fibrosis" is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $683,564.00 over the period of Jul 1, 2025 to Mar 31, 2030. The award supports comprehensive research focused on understanding the role of aberrant alveolar epithelial cells in the pathogenesis of pulmonary fibrosis, a devastating and progressive lung disease. The research aims to investigate...